Costs of the management of hemophilia A with inhibitors in Spain

  • Santiago Bonanad Hospital Universitari i Politècnic La Fe, Valencia - Spain
  • María Teresa Álvarez Hospital Universitario La Paz, Madrid - Spain
  • Ramiro Núñez Hospital Virgen del Rocío, Sevilla - Spain
  • José Luis Poveda Hospital Universitari i Politècnic La Fe, Valencia - Spain
  • Beatriz Gil Roche Farma, Madrid - Spain
  • Elena Ruíz-Beato Roche Farma, Madrid - Spain
  • Ana Durán Weber, Madrid - Spain
  • Yoana Ivanova Weber, Madrid - Spain
  • Inés Pérez-Román Weber, Madrid - Spain
  • Almudena González-Domínguez Weber, Madrid - Spain
Keywords: Activated prothrombin complex concentrate, Costs, Emicizumab, Hemophilia A, Recombinant factor VIIa


Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in adult and pediatric patients, including the prophylaxis with emicizumab.

Methods: We calculated the costs of the on-demand and prophylactic treatments with bypassing agents (activated prothrombin complex concentrate and recombinant activated factor VII) and the emicizumab prophylaxis, from the societal perspective, over 1 year. The study considered direct healthcare costs (drugs, visits, tests, and hospitalizations), direct non-healthcare costs (informal caregivers), and indirect costs (productivity loss). Data were obtained from a literature review and were validated by an expert group. Costs were expressed in 2019 euros.

Results: Our results showed that the annual costs of the prophylactic treatment per patient varied between €543,062.99 and €821,415.77 for adults, and €182,764.43 and €319,826.59 for children, while on-demand treatment was €532,706.84 and €789,341.91 in adults, and €167,523.05 and €238,304.71 in pediatric patients. In relation to other prophylactic therapies, emicizumab showed the lowest costs, with up to a 34% and 43% reduction in the management cost of adult and pediatric patients, respectively. It reduced the bleeding events and administration costs, as this drug is less frequently administered by subcutaneous route. Emicizumab prophylaxis also decreased the cost of other healthcare resources such as visits, tests, and hospitalizations, as well as indirect costs.

Conclusion: In comparison to prophylaxis with bypassing agents, emicizumab reduced direct and indirect costs, resulting in cost savings for the National Health System and society.


Ministerio de Sanidad, Servicios Sociales e Igualdad: Hemofilia. Accessed May 8, 2019.

Grupo de hemostasia y trombosis: Guía asistencial de hemofilia en Castilla y León. Accessed May 8, 2019.

Aznar JA, Altisent C, Álvarez-Román MT, Bonanad S, Mingot-Castellano ME, López MF. Moderate and severe haemophilia in Spain: an epidemiological update. Haemophilia. 2018;24(3):e136-e139. PMID:29578308

Federación Española de Hemofilia (FEDHEMO). Accessed June 3, 2020.

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS): Informe de Posicionamiento Terapéutico de emicizumab (Hemlibra®) en hemofilia A con inhibidores del factor VIII. (2019). Accessed June 20, 2019.

López-Fernández MF, Altisent Roca C, Álvarez-Román MT, et al. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost. 2016;115(5):872-895. PMID:26842562

Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain. Haemophilia. 2015;21(3):320-329. PMID:25855214

Mingot-Castellano ME, Álvarez-Román MT, López-Fernández MF, et al. Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors. Eur J Haematol. 2016;96(5):461-474.

Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol. 2004;77(2):187-193.

Hay CR, Ludlam CA, Colvin BT, et al; UK Haemophilia Centre Directors Organisation. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thromb Haemost. 1998;79(4):762-766. PMID:9569189

Leissinger C, Cooper DL, Solem CT; HTRS Investigators. Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. Haemophilia. 2011;17(6):884-889. PMID:21447095

Walsh CE, Soucie JM, Miller CH; United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400-405. PMID:25616111

European Medicines Agency (EMA). First-in-class medicine to prevent bleeding in haemophilia A patients with inhibitors. Accessed March 12, 2020.

European Medicine Agency: Hemlibra. Ficha técnica o resumen de las características del producto. Accessed June 25, 2019.

Álvarez-Román MT, Cuervo-Arango I, Pérez-Santamarina R, et al. Determining the value contribution of emicizumab (Hemlibra®) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis. Glob Reg Health Technol Assess. 2019;1-8.

Skinner M. Emicizumab prophylaxis improves long-term health-related quality of life (HRQoL) in Persons with Haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies. Accessed February 25, 2020.

Jiménez-Yuste V, Álvarez Román MT, Mingot-Castellano ME, Fernández Mosteirin N, Mareque M, Oyagüez I. Análisis de costes del tratamiento para pacientes con hemofilia A con inhibidor en España. PharmacoEcon Span Res Artic. 2018;15(1-4):25-34.

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS): CIMA. Feiba 25 U/mL polvo y disolvente para solución para perfusión. Ficha técnica o resumen de las características del producto. Accessed May 28, 2019.

Agencia Española de Medicamentos y Productos Sanitarios (AEMPS): CIMA. NovoSeven. Accessed November 6, 2019.

Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.

Young G, Oldenburg J, Liesner R, et al. HAVEN 2: efficacy, safety and pharmacokinetics of once-weekly prophylactic emicizumab (ACE910) in pediatric patients (<12 years) with hemophilia A with inhibitors: interim analysis of single-arm, multicenter, open-label, phase 3 study. American Society of Hematology. 60th ASH Annual Meeting and Exposition; 2018 Dec 1; San Diego, California.

Mahlangu J, Oldenburg J, Callaghan MU, et al. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: a prospective, multi-centre, non-interventional study. Haemophilia. 2018;24(6):921-929. PMID:30295389

Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia. 2006 Jul;12(4):352-362. PMID: 16834734.

National Statistics Institute. Working market. Accessed November 4, 2019.

Aznar JA, Lucía F, Abad-Franch L, et al. Haemophilia in Spain. Haemophilia. 2009;15(3):665-675. PMID:19432921

Consejo General de Colegios Oficiales de Farmacéuticos: Bot Plus 2.0 Base de Datos de Medicamentos. Accessed February 27, 2019.

Ministerio de Sanidad: Listado de Medicamentos afectados por las deducciones del RD 8/2010. Accessed February 27, 2019.

Median value of the unit costs for Autonomous Communities (2019)

Ministerio de Sanidad, Consumo y Bienestar Social. Subdirección General de Información Sanitaria. Registro de Actividad de Atención Especializada – RAE-CMBD. Accessed August 29, 2019.

Bastida JL, Linertová R, Aguilar PS, Hens Pérez M, Posada de la Paz M, Oliva Moreno J. Los costes socioeconómicos y la calidad de vida relacionada con la salud en pacientes con enfermedades raras en España. IMSERSO. 114 (2012). Accessed March 5, 2020.

van den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Eur J Health Econ. 2004;5(1):36-45. PMID:15452763

Zhou Z-Y, Hay JW. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther. 2012;34(2):434-445. PMID:22285208

O’Hara J, Hughes D, Camp C, Burke T, Carroll L, Diego DG. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106. PMID:28569181

Oak B, Nambiar S, Springs S, Eguale T. A comparison of prophylactic versus on-demand treatment regimens of coagulation factor VIII for bleeding and joint outcomes in Hemophilia A patients without inhibitors: a systematic review and meta-analysis. Value Health. 2018;21:S247.

Nugent D, O’Mahony B, Dolan G; International Haemophilia Access Strategy Council. Value of prophylaxis vs on-demand treatment: application of a value framework in hemophilia. Haemophilia. 2018;24(5):755-765. PMID:30088692

Castaman G, Linari S. Prophylactic versus on-demand treatments for hemophilia: advantages and drawbacks. Expert Rev Hematol. 2018;11(7):567-576. PMID:29886751

Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015;21(3):310-319.

Cortesi PA, Castaman G, Trifirò G, et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost. 2020;120(2):216-228. PMID:31887777

Patel AM, Corman SL, Chaplin S, Raimundo K, Sidonio RF. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. J Med Econ. 2019;22(12):1328-1337. PMID:31530050

How to Cite
Bonanad S, Álvarez M, Núñez R, Poveda J, Gil B, Ruíz-Beato E, Durán A, Ivanova Y, Pérez-Román I, González-Domínguez A. Costs of the management of hemophilia A with inhibitors in Spain. GRHTA [Internet]. 1Apr.2021 [cited 19Jun.2021];8:35-2. Available from:
Original Research Article

Most read articles by the same author(s)